The stock of Hims & Hers Health Inc (NYSE:HIMS) last traded at $34.47, down -4.12% from the previous session.
HIMS stock price is now -7.43% away from the 50-day moving average and 37.14% away from the 200-day moving average. The market capitalization of the company currently stands at $7.66B.
With the price target enhanced from $42 to $60, Morgan Stanley Downgraded its rating from Overweight to Equal-Weight for Hims & Hers Health Inc (NYSE: HIMS). On January 10, 2025, Citigroup Downgraded its previous ‘Neutral’ rating to ‘Sell’ on the stock increasing its target price from $24 to quote $25, while ‘BTIG Research’ rates the stock as ‘Buy’
In other news, Becklund Irene, PAO sold 2,913 shares of the company’s stock on Mar 03 ’25. The stock was sold for $131,493 at an average price of $45.14. Upon completion of the transaction, the PAO now directly owns 4,406 shares in the company, valued at $0.15 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 05 ’25, Director Pendarvis Christiane bought 12,500 shares of the business’s stock. A total of $500,000 was incurred on buying the stock at an average price of $40.00. A total of 18.31% of the company’s stock is owned by insiders.
During the past 12 months, Hims & Hers Health Inc has had a low of $11.20 and a high of $72.98. As of last week, the company has a debt-to-equity ratio of 0.02, a current ratio of 1.79, and a quick ratio of 1.50.
The net profit margin was 8.54% and return on equity was 30.71% for HIMS. The company reported revenue of $481.14 million for the quarter, compared to $246.62 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 95.09 percent. For the current quarter, analysts expect HIMS to generate $534.97M in revenue.
